Navigation Links
Commencement of a Phase II Clinical Trial of SG2000 in Ovarian Cancer
Date:9/15/2010

LONDON and NEW YORK, Sept. 15 /PRNewswire/ -- Spirogen Limited (the "Company") and Celtic Therapeutics Holdings LP ("Celtic Therapeutics") announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer.  The trial is being sponsored by the National Cancer Institute (NCI) of the USA, and is now actively recruiting patients for treatment.

The open-label Phase II study will evaluate the overall response rate of SG2000 in approximately 50 patients with recurrent, resistant or refractory epithelial ovarian, primary peritoneal, or fallopian tube carcinoma.  The trial will be conducted at a consortium of four leading southeast U.S. cancer centers, led by Vanderbilt-Ingram Cancer Center, and including Moffitt Cancer Center at the University of South Florida, Winship Cancer Institute at Emory University and Massey Cancer Center at Virginia Commonwealth University.

"We are delighted to have commenced this important trial for SG2000 in platinum-resistant and refractory ovarian cancer.  We believe that if SG2000 demonstrates similar activity in this Phase II trial to that demonstrated in vitro and in patients in four separate Phase I trials with more than 60 patients, it has the potential to be an important new therapeutic for women with ovarian cancer," said Marta Ann Crispens, MD, FACOG, Principal Investigator, Vanderbilt University Medical Center.

Chris Martin, CEO of Spirogen said, "The initiation of this Phase II ovarian cancer trial with SG2000 is an important milestone in developing a new therapy for this high unmet medical need.  We are excited to be working with both the NCI for this trial, including its impressive team of investigators, and also of course Celtic Therapeutics and their very experienced drug development team."

Tomasz Sablinski, MD, Head of Development at Celtic Therapeutics said: "SG2000 is an exciting compound, which acts by a novel mechanism, and may be a very valuable ther
'/>"/>

SOURCE Celtic Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cogdell Spencer Announces Commencement of Common Stock Offering
2. U.S. Surgeon General Dr. Regina M. Benjamin to Deliver Commencement Address at Albany College of Pharmacy and Health Sciences
3. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
4. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
5. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
6. Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
7. Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
8. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
9. First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has Been Published
10. ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmins Potential to Transform the Treatment of Retinal Disorders
11. Transdel Pharmaceuticals Presents Phase 3 Study Data on Ketotransdel® at World Pain Congress in Montreal, Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and MELBOURNE, Australia , ... Nexvet Biopharma today announced the appointments of Dr. ... McCracken D.V.M ., M.S., to its Board of Directors. ... Medical Affairs Finance at Genentech and Chief Financial Officer ... served as Vice President and Global Head of Business ...
(Date:9/18/2014)... JOLLA, Calif. , Sept. 18, 2014 /PRNewswire/ ... RGLS ), a biopharmaceutical company leading the discovery ... today it has initiated its ATHENA natural history ... a life-threatening genetic kidney disease with no approved ... the natural decline of renal function markers such ...
(Date:9/18/2014)... days before the government of Sierra Leone ... Ebola, World Vision will begin a massive delivery of 200 ... McKesson, the largest healthcare services company in ... Medical-Surgical donated four million pairs of latex gloves – enough ... needs for the next five months* – to ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 2World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 3World Vision, McKesson, Other Donors Prepare for Massive Shipment of Medical Supplies to Support Sierra Leone Health Workers 4
... N.C., Feb. 10, 2011 For the biopharmaceutical ... importance - and difficulty - of interacting with ... restrictions have created both opportunities and challenges for ... control. To help marketing teams in ...
... 3-V Biosciences, Inc. announced today Stephen R. Brady has ...   http://photos.prnewswire.com/prnh/20100513/LA04336LOGO ) "Steve,s contributions have been pivotal ... 3-V," said Merdad V. Parsey, MD, PhD, 3-V,s Chief Executive ... continue to build the 3-V team and advance the company,s ...
Cached Medicine Technology:Innovations in Patient-Focused Initiatives to Improve Outcomes 23-V Biosciences Promotes Stephen R. Brady to Chief Business Officer 2
(Date:9/18/2014)... CRDF Global released today its ... edition – rich with videos, images and interactive ... Global empowers scientists and innovators around the world. ... foundation and individual supporters, CRDF Global reaches across ... training and entrepreneurship. , The Annual Report highlights ...
(Date:9/18/2014)... 18, 2014 Phela Health and Wellness ... HABIT™ Program in South Africa. HABIT™ is a ... and distributed in South Africa by Bestflex. , Phela ... which has been tailored to address issues that are ... behavior modification and chronic disease prevention. This solution combines ...
(Date:9/18/2014)... 2014) A new expert panel report, Improving ... the Council of Canadian Academies, addresses the importance ... Each year about half of Canada,s seven million ... of this prescribing is done off-label (i.e. the ... health risks., Children have historically been excluded in ...
(Date:9/18/2014)... Dr. Andrea Basile, MD, one of the most ... at Basile Plastic Surgery to include Coolsculpting. This non-invasive technique ... in the world for the removal of fat because of ... Dr. Basile, Coolsculpting will greatly benefit those patients with body ... procedure. He also said this procedure is ideal for people ...
(Date:9/18/2014)... 18, 2014 The new BuildClean™ ... to contractors and homeowners alike as it eliminates ... the home, causes potential health issues, and makes ... the BuildClean system allows contractors to virtually eliminate ... other standard remodeling tasks. , BuildClean removes up ...
Breaking Medicine News(10 mins):Health News:CRDF Global Launches Media-Rich Digital Edition of Annual Report, Tells Story of Empowering Scientists and Innovators around the World in 2013 2Health News:Improving medicines for children in Canada 2Health News:Naples Plastic Surgeon Introduces Pain-free Fat Removal Technique 2Health News:Naples Plastic Surgeon Introduces Pain-free Fat Removal Technique 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 2Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 3Health News:New BuildClean™ System Brings Livability Back to Home Remodeling 4
... Research Group is,an exciting newcomer in the field ... information service established to,provide the general public with ... choose for a variety of medical problems resulting ... the website will be,obtained through an online survey ...
... of the,Board and Chief Executive Officer, A.G. Lafley, addressed ... at its annual meeting today. Lafley,said, "P&G is a ... long term,-- consistently, reliably and sustainably." Growth in ... fiscal 2007. P&G increased,net sales by 12 percent to ...
... UPCARE(R) E2E, an end-to-end, financial and clinical ... for laboratories. -- ... Mich., Oct. 9 Today, UPCARE Technology, Inc.,unveiled its new ... part on the success of its parent company, Marquette,General Health ...
... three scientists receiving the 2007 Nobel Prize for Physiology or ... their careers, bringing to 42 the number of Nobel Laureates ... Capecchi, Ph.D. of the University of Utah and Oliver Smithies, ... with Sir Martin J. Evans of Cardiff University in Wales ...
... Nutrition,(OTC Bulletin Board: NNTN) http://www.interactivenutrition.com will ... 2007 at,11:00 a.m. Eastern time. U.S. and Canadian ... 800-750-4065 and International Shareholders may dial in at,404-920- ... 767872#. Executives,from Natural Nutrition will be available for ...
... Exchange Symbol: AKL, MONTREAL, Oct. 9 /PRNewswire-FirstCall/ ... company focused on developing therapies for the,inhalation, pain ... 2007, its issued and outstanding common shares will ... common share for every seven (7),pre-consolidation common shares. ...
Cached Medicine News:Health News:Nursesavvy.com Promoting Quality Healthcare for Everyone 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 2Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 3Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 4Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 5Health News:Lafley Tells Shareholders That 'P&G is Designed to Grow' 6Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 2Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 3Health News:UPCARE Technology to Share the Secrets of its Parent's Success in Lab Outreach 4Health News:Natural Nutrition to Hold International Shareholder Conference Call Thursday, October 11, 2007 at 11:00 a.m. Eastern Time 2Health News:Akela Pharma Inc. Completes Share Consolidation 2
BioScrew® Bio-Absorbable Interference Screws and Delivery System Clinically equivalent to metal interference screws....
... Interference Screws. Optimal screw ... graft selection options. Robust ... deformation, and chamfered screw ... atraumatic tissue fixation. Features ...
Cannulated Interference Screws...
... on the TrueView II design, a new ... for small joint arthroscopy is available. The ... very durable thanks to Olympus advanced fibre ... class means bright images, brilliant colour reproduction, ...
Medicine Products: